Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · Real-Time Price · USD
10.32
-0.11 (-1.05%)
At close: May 16, 2025, 4:00 PM
10.26
-0.06 (-0.58%)
After-hours: May 16, 2025, 4:05 PM EDT
Cartesian Therapeutics Stock Forecast
Stock Price Forecast
According to 5 professional analysts, the 12-month price target for Cartesian Therapeutics stock ranges from a low of $40 to a high of $43. The average analyst price target of $41 forecasts a 297.29% increase in the stock price over the next year.
Price Target: $41.00 (+297.29%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Cartesian Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
---|---|---|---|---|---|---|
Strong Buy | 6 | 6 | 6 | 6 | 6 | 6 |
Buy | 1 | 1 | 1 | 1 | 1 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 8 | 8 | 8 | 8 | 8 | 7 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Needham | Needham | Strong Buy Maintains $41 → $40 | Strong Buy | Maintains | $41 → $40 | +287.60% | May 8, 2025 |
Needham | Needham | Strong Buy Reiterates $41 | Strong Buy | Reiterates | $41 | +297.29% | Apr 9, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +287.60% | Apr 9, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $45 → $40 | Strong Buy | Maintains | $45 → $40 | +287.60% | Mar 14, 2025 |
Needham | Needham | Strong Buy Reiterates $41 | Strong Buy | Reiterates | $41 | +297.29% | Mar 13, 2025 |
Financial Forecast
Revenue This Year
3.40M
from 38.91M
Decreased by -91.26%
Revenue Next Year
n/a
from 3.40M
EPS This Year
-3.11
from -4.49
EPS Next Year
-3.64
from -3.11
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 21.0M | n/a | n/a | ||
Avg | 3.4M | n/a | n/a | ||
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -46.0% | - | - | ||
Avg | -91.3% | - | - | ||
Low | - | - | - |
EPS Forecast
EPS | 2025 | 2026 | 2027 |
---|---|---|---|
High | -2.26 | -2.07 | -3.53 |
Avg | -3.11 | -3.64 | -4.55 |
Low | -3.81 | -4.36 | -5.83 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 |
---|---|---|---|
High | - | - | - |
Avg | - | - | - |
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.